Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy

NCT01498887 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

347

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsing Remitting Multiple Sclerosis

Interventions

DRUG: Fingolimod (FTY720)

Sponsor

Novartis Pharmaceuticals